Our results showed that inhibiting SLC26A4 suppressed cardiac hypertrophy, as determined by the down-regulation of ANP and BNP (Li et al., 2017) and the up-regulation of GSK-3β. The gene discussed is GSK3B; the disease is cardiac hypertrophy.